Literature DB >> 10863060

Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function.

E E Yeoh1, R Botten, A Russo, R McGowan, R Fraser, D Roos, M Penniment, M Borg, W Sun.   

Abstract

PURPOSE: To evaluate prospectively the prevalence and pathophysiology of anorectal dysfunction following radiation therapy (RTH) for localized carcinoma of the prostate. METHODS AND MATERIALS: The following parameters of anorectal function were evaluated in each of 35 patients (aged 55-82 years) with localized prostatic carcinoma treated with RTH either to a dose of 55 Gy/20 fractions/4 weeks (18 patients) or 64 Gy/32 fractions/6.5 weeks (17 patients), before RTH and 4-6 weeks and at a mean (+/- SD) of 1.4 (+/- 0.2) years after its completion: (1) anorectal symptoms (questionnaire), (2) anorectal pressures at rest and in response to voluntary squeeze and increases in intra-abdominal pressure (multiport anorectal manometry), (3) rectal sensation (balloon distension) and (4) anal sphincteric morphology (endoanal ultrasound).
RESULTS: All but 1 patient completed three series of measurements. RTH had no effect on anal sphincteric morphology. The increase in frequency of defecation and fecal urgency and incontinence scores previously reported in the patients 4-6 weeks after RTH were sustained 1 year later (p < 0.001, p < 0.001, and p < 0.05, cf. baseline, respectively). At this time, 56% (19 of 34), 50% (17 of 34) and 26% (9 of 34) of the patients had increased frequency of defecation, fecal urgency, and incontinence, respectively. Decreases in anal sphincteric pressures at rest and in response to voluntary squeeze recorded in the patients 4-6 weeks after RTH were not sustained 1 year later but the volumes of rectal distension associated with perception of the stimulus and desire to defecate were lower compared with baseline volumes (p < 0.01 and p < 0.05, respectively), reflecting heightened rectal sensitivity in the patients. There was no difference in measurements between the two radiation dose regimens. Univariate logistical regression analysis was performed on patients who had experienced increased symptom scores or decreases in recorded motor and sensory manometric parameters at 1 year, cf. baseline. The predictor variables used included individual patient tumor and treatment characteristics as well as individual patient symptom scores and parameters of anorectal motor and sensory function at baseline and 4-6 weeks after RTH. The results of the univariate logistical regression analysis showed that (1) frequency of defecation at 4-6 weeks and (2) rectal volumes at baseline both for (a) perception (p < 0.001) and (b) desire to defecate (p < 0.001), predicted significantly for the patients who had symptoms and signs of anorectal dysfunction at 1 year. Individual patient tumor and treatment-related variables tested, in contrast, had no predictive significance.
CONCLUSIONS: Anorectal symptoms following RTH for prostatic carcinoma are common and persist at least until 1 year after its completion and are associated with objective evidence of heightened rectal sensitivity.

Entities:  

Mesh:

Year:  2000        PMID: 10863060     DOI: 10.1016/s0360-3016(00)00487-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

Review 1.  Effects of radiation therapy on the structure and function of the pelvic floor muscles of patients with cancer in the pelvic area: a systematic review.

Authors:  Stéphanie Bernard; Marie-Pier Ouellet; Hélène Moffet; Jean-Sébastien Roy; Chantale Dumoulin
Journal:  J Cancer Surviv       Date:  2015-08-28       Impact factor: 4.442

2.  Effectiveness of sacral nerve stimulation in fecal incontinence after multimodal oncologic treatment for pelvic malignancies: a multicenter study with 2-year follow-up.

Authors:  M Schiano di Visconte; G A Santoro; N Cracco; G Sarzo; G Bellio; M Brunner; Z Cui; K E Matzel
Journal:  Tech Coloproctol       Date:  2018-01-08       Impact factor: 3.781

3.  Neoadjuvant radiochemotherapy for patients with locally advanced rectal cancer leads to impairment of the anal sphincter.

Authors:  Joerg Theisen; Werner K-H Kauer; Hjalmar Nekarda; Ludwig Schmid; Hubert J Stein; Joerg-Ruediger Siewert
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

4.  Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer.

Authors:  Keith Rourke; Adam Kinnaird; Jeff Zorn
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

Review 5.  Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations.

Authors:  Y Ziv; A Zbar; Y Bar-Shavit; I Igov
Journal:  Tech Coloproctol       Date:  2012-10-18       Impact factor: 3.781

6.  Gastrointestinal complications of pelvic radiotherapy: are they of any importance?

Authors:  J Andreyev
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 7.  Systematic review: anal and rectal changes after radiotherapy for prostate cancer.

Authors:  Robin Krol; Robert Jan Smeenk; Emile N J T van Lin; Eric E K Yeoh; Wim P M Hopman
Journal:  Int J Colorectal Dis       Date:  2013-10-23       Impact factor: 2.571

8.  Urethroplasty after radiation therapy for prostate cancer.

Authors:  Allison S Glass; Jack W McAninch; Uwais B Zaid; Nadya M Cinman; Benjamin N Breyer
Journal:  Urology       Date:  2012-04-21       Impact factor: 2.649

Review 9.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

10.  Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding.

Authors:  Michael Pinkawa; Marc D Piroth; Karin Fischedick; Sandra Nussen; Jens Klotz; Richard Holy; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-09-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.